scholarly journals Metastatic Breast Cancer Presenting as Fulminant Hepatic Failure: A Case Report and Literature Review

1989 ◽  
Vol 3 (4) ◽  
pp. 149-152 ◽  
Author(s):  
Malcolm S. Trimble ◽  
Cameron N. Ghent ◽  
David R. Grant ◽  
Caroline A. McLean
Keyword(s):  
Breast Cancer ◽  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Fulminant Hepatic Failure ◽  
Hepatic Failure ◽  
Metastatic Breast ◽  
Metastatic Carcinoma ◽  
Metastatic Breast Carcinoma

A case of metastatic breast carcinoma presenting as fatal fulminant hepatic failure is presented. The patient did not have previously diagnosed breast cancer and presented with ascites, Jaundice, abdominal pain, nausea, vomiting and hepatic encephalopathy. She died within four weeks of the onset. Seven similar cases previously reported are reviewed. Metastatic carcinoma should he considered in the differential diagnosis of fulminant hepatic failure.

scholarly journals Gemcitabine-Induced Radiation Recall Myositis: Case Report and Review of the Literature

2018 ◽  
Vol 11 (1) ◽  
pp. 168-178 ◽  
Author(s):  
Adarsh Ravishankar ◽  
Sean S. Park ◽  
Kenneth R. Olivier ◽  
Kimberly S. Corbin
Keyword(s):  
Breast Cancer ◽  
Differential Diagnosis ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Inflammatory Reaction ◽  
Clinical Course ◽  
Postoperative Radiotherapy ◽  
Metastatic Breast ◽  
Review Of The Literature ◽  
Radiation Recall

Gemcitabine-induced radiation recall (GIRR) is a phenomenon wherein the administration of gemcitabine induces an inflammatory reaction within an area of prior radiation. We present the case of a 39-year-old female patient with metastatic breast cancer who experienced GIRR myositis 3 months following postoperative radiotherapy, with additional potential paraspinal myositis following ablative radiotherapy to the thoracic spine. A review of previously published cases of GIRR myositis was performed. The case and literature review describe the clinical course and presentation of GIRR, and highlight the importance of including radiation recall as part of a differential diagnosis when a patient undergoing chemotherapy experiences an inflammatory reaction at a prior site of radiation.

Surviving Metastatic Breast Cancer for 18 Years: A Case Report and Review of the Literature

2011 ◽  
Vol 17 (5) ◽  
pp. 521-524 ◽  
Author(s):  
Soley Bayraktar ◽  
Monica T. Garcia-Buitrago ◽  
Erin Hurley ◽  
Stefan Gluck
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Review Of The Literature

scholarly journals Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

2020 ◽  
Vol 13 (1) ◽  
pp. 304-308 ◽  
Author(s):  
Alyssa Schlotman ◽  
Adam Stater ◽  
Kyle Schuler ◽  
Judd Heideman ◽  
Vandana Abramson
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Hepatotoxic Effect ◽  
Er Positive ◽  
Grade 3 ◽  
Experienced Grade

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.

scholarly journals Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 544-549
Author(s):  
Giacomina Megaro ◽  
Luigi Rossi ◽  
Serena Ceddia ◽  
Marsela Sinjari ◽  
Adele Mannino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Disease Control ◽  
Endocrine Therapy ◽  
Biological Markers ◽  
Metastatic Breast ◽  
Control Therapy

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

2019 ◽  
Vol 130 ◽  
pp. 267-270
Author(s):  
Yoshifumi Tao ◽  
Kenji Yagi ◽  
Hirotake Nishimura ◽  
Keijirou Hara ◽  
Shunji Matsubara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Bone Cyst ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.

1993 ◽  
Vol 11 (3) ◽  
pp. 461-466 ◽  
Author(s):  
J E Perez ◽  
M Machiavelli ◽  
B A Leone ◽  
A Romero ◽  
M G Rabinovich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Complete Response ◽  
Severe Toxicity ◽  
First Line ◽  
Metastatic Breast Carcinoma ◽  
Time To Treatment Failure ◽  
Grade 3 ◽  
Line Chemotherapy

PURPOSE A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma. PATIENTS AND METHODS Between January 1990 and August 1991, 48 patients with metastatic breast cancer were entered onto the study. Therapy consisted of IFX 2 g/m2 given as a 1-hour intravenous (IV) infusion on days 1 to 3; mesna 400 mg/m2 as an IV bolus immediately before and 4 hours after IFX administration and 2,000 mg orally 8 hours after IFX administration on days 1 to 3; and MXN 12 mg/m2 as an i.v. bolus on day 3. Cycles were repeated every 21 days until progressive disease (PD) or severe toxicity developed. RESULTS One patient was considered not assessable for response. Objective regression (OR) was observed in 28 of 47 patients (60%; 95% confidence interval, 46% to 74%). Six patients (13%) had a complete response (CR) and 22 (47%) had a partial response (PR). The median time to treatment failure for the whole group was 9 months (range, 1 to 28); median survival was 19 months (range, 2 to 28). There were no treatment-related deaths. The limiting toxicity was myelosuppression. Leukopenia occurred in 37 patients (77%) and was grade 3 or 4 in 19 patients (40%). Nausea and vomiting were observed in 38 patients (80%), mucositis in 16 patients (33%), and grade 2 hematuria in two patients (4%). Eight patients (16%) developed mild neurotoxicity. CONCLUSION The combination of IFX plus MXN is an active regimen against metastatic breast cancer with moderate toxicity that deserves further evaluation.

scholarly journals The potential role of HER 2 upregulation in metastatic breast cancer to the uterus: a case report

2016 ◽  
Vol 4 (10) ◽  
pp. 928-934 ◽  
Author(s):  
Melissa Y. Y. Moey ◽  
Omer A. Hassan ◽  
Christos N. Papageorgiou ◽  
Stephanie L. Schnepp ◽  
John T. Hoff
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Potential Role ◽  
Metastatic Breast ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document